Practical reading from Professor Paul Lee and the Lincolnshire Hip Clinic team — across hip replacement, Arthrosamid, ChondroFiller, PRP and the wider world of hip and groin pain.
Hip cartilage defects in active adults can now be treated via outpatient injection or arthroscopic surgery, but choosing between them is not determined by invasiveness alone — they work through fundamentally different mechanisms and suit different lesion profiles.
ChondroFiller hip recovery depends on the patient's own progenitor cells integrating into a collagen scaffold over months—the scaffold gels within minutes, but meaningful improvement appears between months three and six.
Hip pain that disrupts sleep does not necessarily indicate worsening disease. Movement pumps synovial fluid through the joint and clears inflammatory chemicals; once movement stops, those chemicals pool and press on nerve endings. Daytime activity also filters pain signals from awareness; in the quiet of night, the brain registers them fully.
Cartilage damage type, not pain severity, determines which hip injection is appropriate: ChondroFiller recruits the body's repair cells for focal defects; Arthrosamid provides permanent cushioning for diffuse wear, though licensed for knees only.
Over 19,000 ChondroFiller hip injections have been administered since 2013 with no serious adverse effects and a complaint rate of 0.06% — though the safety data apply specifically to focal cartilage defects with intact borders, not diffuse hip osteoarthritis.
ChondroFiller's collagen scaffold must be placed precisely in the cartilage defect to work; if it disperses into joint fluid, the treatment fails entirely. Ultrasound guidance achieves 97–100% accuracy; landmark technique achieves 72%.
ChondroFiller injection uses a collagen scaffold to recruit the patient's own progenitor cells for cartilage repair; it costs £3,000–£8,000 and remains unavailable on the NHS.
A ChondroFiller hip injection costs £6,500–£9,500 in the UK. The collagen scaffold triggers the patient's progenitor cells to regenerate cartilage in the focal defect—a cellular mechanism that distinguishes it from standard steroid and lubrication injections and accounts for its higher cost.
Hip cartilage has no blood supply and cannot repair itself once damaged to exposed bone. Two injectable treatments — ChondroFiller gel and autologous stem cells — aim to trigger biological repair for focal defects, but address different disease stages and carry asymmetric evidence burdens in current hip practice.
Lincolnshire Hip Clinic
Led by Professor Paul Lee
Start with a free, non-medical discovery call with our team. We will tell you, honestly, which of our pathways — surgical or non-surgical — fits your situation. No GP referral, no pressure to proceed.
What we offer
